Immunotherapy breakthrough for brain cancer at UCLA

Summary: Researchers at UCLA developed a new immunotherapy for malignant gliomas, combining a personalized dendritic cell vaccine with poly-ICLC to enhance the immune response. This treatment significantly boosts T cell activity against brain tumors, potentially improving patient outcomes. Initial results show increased interferon response, correlating with longer survival. Further studies are needed to confirm these promising findings. The study was funded by the National Cancer Institute.

Full article